Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Price Target Raised to $100.00 at Citigroup

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price target lifted by Citigroup from $60.00 to $100.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Citigroup’s price objective suggests a potential upside of 27.34% from the stock’s current price.

Other research analysts also recently issued research reports about the company. Zacks Research upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a report on Wednesday, June 17th. Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a report on Monday, July 13th. Wedbush lifted their price target on Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, June 29th. Canaccord Genuity Group raised their price objective on Kiniksa Pharmaceuticals International from $62.00 to $64.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th. Finally, Jefferies Financial Group raised their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the stock a “buy” rating in a report on Tuesday, April 28th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Kiniksa Pharmaceuticals International presently has an average rating of “Buy” and a consensus target price of $73.71.

Kiniksa Pharmaceuticals International Stock Down 1.1%

Shares of Kiniksa Pharmaceuticals International stock opened at $78.53 on Wednesday. The business has a fifty day simple moving average of $57.59 and a 200-day simple moving average of $50.44. Kiniksa Pharmaceuticals International has a fifty-two week low of $29.66 and a fifty-two week high of $81.97. The firm has a market cap of $6.04 billion, a price-to-earnings ratio of 88.28 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last issued its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.30. The company had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. Analysts anticipate that Kiniksa Pharmaceuticals International will post 1.25 earnings per share for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 48,565 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the sale, the chief executive officer directly owned 48,565 shares in the company, valued at approximately $2,623,481.30. This trade represents a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the completion of the transaction, the insider directly owned 65,623 shares in the company, valued at approximately $3,524,611.33. The trade was a 47.10% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 109,130 shares of company stock worth $5,877,070 in the last quarter. 51.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of hedge funds and other institutional investors have recently made changes to their positions in KNSA. EverSource Wealth Advisors LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 140.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after purchasing an additional 532 shares during the last quarter. Osaic Holdings Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International during the second quarter worth $31,000. KBC Group NV acquired a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at about $34,000. Smartleaf Asset Management LLC bought a new position in Kiniksa Pharmaceuticals International during the fourth quarter worth about $36,000. Finally, Nano Cap New Millennium Growth Fund L P acquired a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth about $41,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.